Three-step chemotherapy treatment for platinum-sensitive recurrent ovarian cancer: a review of 20 cases

蔡树模; 汤　洁; 黄　啸; 黄晓炜; 刘素萍; 柯桂好; 郑　重; 程　玺; 唐美琴

doi:10.19401/j.cnki.1007-3639.2021.04.013

您当前的位置：

首页 >

文章列表页 >

Three-step chemotherapy treatment for platinum-sensitive recurrent ovarian cancer: a review of 20 cases

更新时间：2026-01-27

- Three-step chemotherapy treatment for platinum-sensitive recurrent ovarian cancer: a review of 20 cases
- China Oncology Vol. 31, Issue 4, Pages: 330-334(2021)
- 作者机构：
  
  复旦大学附属肿瘤医院妇瘤科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2021.04.013
  CLC： R737.31
- Published Online：29 April 2021，
  
  Published：29 April 2021
- 稿件说明：
移动端阅览
蔡树模, 汤　洁, 黄　啸, 黄晓炜, 刘素萍, 柯桂好, 郑　重, 程　玺, 唐美琴. 铂类药物敏感复发卵巢癌患者的三步化疗法附20例分析[J]. 中国癌症杂志, 2021, 31(4): 330-334.

蔡树模, 汤　洁, 黄　啸, et al. Three-step chemotherapy treatment for platinum-sensitive recurrent ovarian cancer: a review of 20 cases[J]. China Oncology, 2021, 31(4): 330-334.
蔡树模, 汤　洁, 黄　啸, 黄晓炜, 刘素萍, 柯桂好, 郑　重, 程　玺, 唐美琴. 铂类药物敏感复发卵巢癌患者的三步化疗法附20例分析[J]. 中国癌症杂志, 2021, 31(4): 330-334. DOI： 10.19401/j.cnki.1007-3639.2021.04.013.

蔡树模, 汤　洁, 黄　啸, et al. Three-step chemotherapy treatment for platinum-sensitive recurrent ovarian cancer: a review of 20 cases[J]. China Oncology, 2021, 31(4): 330-334. DOI： 10.19401/j.cnki.1007-3639.2021.04.013.

摘要

背景与目的：晚期卵巢癌患者治疗后80%会复发，中位无进展生存期（progression-free survival，PFS）为20个月。复发后的卵巢癌已不能治愈，只能延长生存期，改善生活质量。对铂类药物敏感首次复发的卵巢癌，设计三步化疗法，以期提高疗效。方法：2010年5月—2016年12月复旦大学附属肿瘤医院妇瘤科收治铂类药物敏感首次复发卵巢癌，经紫杉醇联合铂类药物化疗取得缓解者20例，患者均接受三步化疗法：① 紫杉醇+卡铂，每3周给药1次，共6个周期；② 奈达铂+依托泊苷+环磷酰胺，每4周给药1次，共5个周期，紫杉醇+卡铂，每4~6周给药1次，共4个周期；③ 奈达铂+依托泊苷+环磷酰胺，每8周给药1次，共5个周期。结果：20例患者4年无病生存率（disease-free survival，DFS）为65.0%（13/20），5年DFS为61.5%（8/13），4年、5年生存率均为100.0%（20/20，13/13）。结论：采用三步化疗法治疗铂类药物敏感复发卵巢癌，能提高疗效。三步化疗法疗效高，治疗费用较低，值得进一步临床研究。

Abstract

Background and purpose: Over 80% of advanced ovarian cancer will recur after primary treatment with a median progression-free survival time of 20 months. Patients with recurrent ovarian cancer can’t be cured

but can achieve longer life span and improved life of quality. This study proposed to design a three-step chemotherapy regimen for firstly relapsed platinum-sensitive ovarian cancer to improve survival outcomes. Methods: From May 2010 to December 2016

20 patients with platinum-sensitive first relapsed ovarian cancer were treated in the Department of Gynecology and Oncology

Fudan University Shanghai Cancer Center. All patients received three-step chemotherapy. The three-step chemotherapy regimen included: ① paclitaxel+carboplatin

administered once every 3 weeks

a total of 6 cycles; ② nedaplatin+etoposide+cyclophosphamide

administered once every 4 weeks

total 5 cycles followed by paclitaxel+carboplatin

administered once every 4-6 weeks

a total of 4 cycles; ③ nedaplatin+etoposide+ cyclophosphamide

administered once every 8 weeks

a total of 5 cycles. Results: The 4-year disease-free survival (DFS) rate and the 5-year DFS rate were 65.0% (13/20) and 61.5% (8/13)

respectively. The 4-year and 5-year survival rates were both 100% (20/20 and 13/13). Conclusion: Three-step chemotherapy regimen is correlated to improved survival outcomes for patients with platinum- sensitive recurrent ovarian cancer. Due to its promising effects and low costs

potential value of this treatment strategy is worth further exploration.

关键词

Keywords

references

Views

2655

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Leading research progress and prospect of gynecological oncology in 2020

The relapse of primary cardiac high-grade B-cell lymphoma after remission: a case report

Three-step chemotherapy after primary debulking surgery in 15 patients with stage Ⅲc or Ⅳovarian cancer

Chinese expert consensus on whole-process management of chemotherapy-related diarrhea (2025 edition)

Effectiveness and safety analysis of camrelizumab combined with chemotherapy and targeted therapy in patients with recurrent, metastatic, and treatment-naive advanced cervical cancer: a retrospective cohort study

Related Author

朱　俊

吴小华

李　磊

王　智

由春媛

汤洁

黄啸

Association Committee of Rehabilitation and Palliative Care China Anti-Cancer

Related Institution

南京医科大学附属无锡第二医院心内科

南京医科大学附属无锡第二医院血液科

Department of Surgical Oncology, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Pharmacy, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Diagnostic Radiology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰